Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$68.12 USD
+1.62 (2.44%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $68.12 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$68.12 USD
+1.62 (2.44%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $68.12 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
Zacks News
OCPNY vs. EW: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
OCPNY vs. EW: Which Stock Is the Better Value Option?
Top Stock Reports for Eli Lilly, ConocoPhillips & PNC Financial
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), ConocoPhillips (COP), and The PNC Financial Services Group, Inc. (PNC).
Why Is Edwards Lifesciences (EW) Down 11.8% Since Last Earnings Report?
by Zacks Equity Research
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights Comcast, CME Group, Charter Communications, Airbnb, and Edwards Lifesciences
by Zacks Equity Research
Comcast, CME Group, Charter Communications, Airbnb, and Edwards Lifesciences are part of Top analyst Blog.
Top Analyst Reports for Comcast, CME & Charter Communications
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Comcast Corporation (CMCSA), CME Group Inc. (CME), and Charter Communications, Inc. (CHTR).
Here's Why You Should Hold on to Edwards Lifesciences (EW) Now
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences (EW) given the strong demand for its RESILIA tissue valves and the PASCAL system.
The Zacks Analyst Blog Highlights T-Mobile US, Deere, PayPal, The PNC Financial Services Group and Edwards Lifesciences
by Zacks Equity Research
T-Mobile US, Deere, PayPal, The PNC Financial Services Group and Edwards Lifesciences have been included in this Analyst Blog.
Top Research Reports for T-Mobile, Deere & PayPal
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), Deere & Company (DE), and PayPal Holdings, Inc. (PYPL).
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
IART vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
IART vs. EW: Which Stock Is the Better Value Option?
Edwards Lifesciences (EW) Q1 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Increased adoption of the PASCAL platform along with continued strength in the HemoSphere monitoring platform drove Edwards Lifesciences' (EW) Q1 revenues.
Edwards Lifesciences (EW) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 3.45% and 2.44%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Humana (HUM) Gears Up For Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Humana's (HUM) first-quarter earnings are likely to reflect the impacts of elevated costs related to investments in technology advancements, partly offset by higher premiums in the Retail segment and sound membership growth.
Edwards Lifesciences (EW) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Improvement in TAVR and TMTT businesses is expected to have contributed to Edwards Lifesciences' (EW) first-quarter performance.
Edwards Lifesciences (EW) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Edwards Lifesciences (EW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Edwards Lifesciences (EW) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Edwards Lifesciences (EW) closed at $121.91 in the latest trading session, marking a +0.89% move from the prior day.
Abiomed (ABMD) Announces Successful Usage of Impella in Japan
by Zacks Equity Research
Continued adoption of Abiomed's (ABMD) Impella 5.5 with SmartAssist is likely to provide a minimally invasive surgical option for acute heart failure patients.
Cardinal Health (CAH) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.
AmerisourceBergen's (ABC) Venture Capital Fund to Aid Healthcare
by Zacks Equity Research
AmerisourceBergen's (ABC) new corporate venture capital fund to help emerging healthcare startup companies change healthcare for people and animals globally.
Here's Why You Should Retain West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.
AmerisourceBergen (ABC) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about AmerisourceBergen's (ABC) strength in its World Courier business.
Edwards Lifesciences' (EW) Global Sales Robust Amid Cost Woes
by Zacks Equity Research
Edwards Lifesciences (EW) is registering robust HemoSphere sales in the United States.
PerkinElmer (PKI) Boosts In Vivo Imaging Profile With New System
by Zacks Equity Research
PerkinElmer's (PKI) launch of the Vega imaging system is likely to help the company expand its in vivo imaging portfolio.
PerkinElmer's (PKI) New Assay Kits to Detect CHO HCP Impurities
by Zacks Equity Research
PerkinElmer (PKI) launches ready-to-use HTRF and AlphaLISA no-wash assay kits to quickly identify and quantify CHO HCP impurities.
Catalent's (CTLT) Latest Buyout to Expand Its Global Footprint
by Zacks Equity Research
Catalent's (CTLT) latest acquisition is likely to significantly enhance its global Biologics business.